Spero Therapeutics Management
Management criteria checks 2/4
Spero Therapeutics' CEO is Sath Shukla, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is $2.02M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.068% of the company’s shares, worth $35.64K. The average tenure of the management team and the board of directors is 1.8 years and 10.6 years respectively.
Key information
Sath Shukla
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 25.9% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.07% |
| Management average tenure | 1.8yrs |
| Board average tenure | 10.6yrs |
Recent management updates
Recent updates
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Nov 02
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Jul 15Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$23m |
| Dec 31 2023 | US$2m | US$524k | US$23m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$2m | US$478k | -US$46m |
| Sep 30 2022 | n/a | n/a | -US$102m |
| Jun 30 2022 | n/a | n/a | -US$113m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$2m | US$441k | -US$90m |
Compensation vs Market: Sath's total compensation ($USD2.02M) is above average for companies of similar size in the US market ($USD654.40K).
Compensation vs Earnings: Sath's compensation has been consistent with company performance over the past year.
CEO
Sath Shukla (51 yo)
1.3yrs
Tenure
US$2,024,647
Compensation
Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman of the Board | 11.3yrs | US$2.39m | 0.43% $ 223.0k | |
| President | 1.3yrs | US$2.02m | 0.068% $ 35.6k | |
| Chief Operating Officer | 1.8yrs | US$1.44m | 0.12% $ 64.6k | |
| CFO, Chief Business Officer & Treasurer | 1.3yrs | no data | 0.063% $ 32.9k | |
| Chief Human Resource Officer | 3.1yrs | no data | no data |
1.8yrs
Average Tenure
48yo
Average Age
Experienced Management: SPRO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman of the Board | 11.3yrs | US$2.39m | 0.43% $ 223.0k | |
| President | 1.3yrs | US$2.02m | 0.068% $ 35.6k | |
| Independent Director | 7.4yrs | US$88.83k | 0.028% $ 14.3k | |
| Independent Director | 10.9yrs | US$105.70k | 0.058% $ 30.0k | |
| Scientific Advisors | 10.6yrs | no data | no data | |
| Clinical Advisor | 10.6yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Lead Independent Director | 9.3yrs | US$93.19k | 0.028% $ 14.3k | |
| Clinical Advisor | 10.6yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Clinical Advisor | 10.6yrs | no data | no data | |
| Independent Director | 5.8yrs | US$73.20k | 0.028% $ 14.3k |
10.6yrs
Average Tenure
58yo
Average Age
Experienced Board: SPRO's board of directors are seasoned and experienced ( 10.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spero Therapeutics, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |